AstraZeneca PLC
AZN Healthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024. In the quarter to June 2026, revenue grew 6.41%, EPS grew 1.90%, free cash flow fell 107.5% and total debt fell 5.50%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five; insiders bought in the last twelve months.
Follow AZN
Alert me
AstraZeneca PLC (AZN) EV/Sales
As of 30 October 2026, AstraZeneca PLC (AZN) trades at a EV/Sales of 5.1×. Over the past ten years it has ranged from 3.2× (March 2016) to 7.1× (March 2015); the current reading is higher than 55% of that period. That is above the Drug Manufacturers General industry median of 4.3× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.0× | 20.35% |
| FY2024 | 4.2× | (16.17%) |
| FY2023 | 5.0× | (5.62%) |
| FY2022 | 5.3× | 4.79% |
| FY2021 | 5.0× | (7.38%) |
| FY2020 | 5.4× | (7.50%) |
| FY2019 | 5.9× | 18.15% |
| FY2018 | 5.0× | 11.21% |
| FY2017 | 4.5× | 26.51% |
| FY2016 | 3.5× | (7.48%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 5.2× | (4.88%) |
| Mar 2026 | 5.5× | 9.09% |
| Dec 2025 | 5.0× | 14.23% |
| Sep 2025 | 4.4× | 2.83% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BMY Bristol Myers Squibb Company compare | 3.2× |
| PFE Pfizer Inc. compare | 3.5× |
| NVO Novo Nordisk A/S compare | 3.7× |
| AZN AstraZeneca PLC | 5.1× |
| NVS Novartis AG compare | 6.1× |
| MRK Merck & Co., Inc. compare | 6.2× |
| GILD Gilead Sciences, Inc. compare | 7.7× |
| AMGN Amgen Inc. compare | 7.7× |
| ABBV AbbVie Inc. compare | 9.1× |
| Drug Manufacturers General industry median | 4.3× |
| Healthcare sector median | 3.6× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)